Connect Biopharma appoints James A. Schoeneck to board of directors

Connect Biopharma Holdings Ltd

Board size increased from six to seven; Schoeneck appointed effective July 22, 2025.
Schoeneck is former CEO of Depomed (2011-2017) and BrainCells (2005-2011).
Currently serves as independent director and chairman at FibroGen and Calidi Biotherapeutics.
Board determined Schoeneck is independent under Nasdaq rules.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.